Teladoc Health Appoints New Director, Adjusts CMO Compensation
Ticker: TDOC · Form: 8-K · Filed: 2024-10-01T00:00:00.000Z
Sentiment: neutral
Topics: executive-compensation, board-changes, personnel
Related Tickers: TDOC
TL;DR
TDOC board shakeup & new CMO pay deal announced.
AI Summary
Teladoc Health, Inc. announced on September 27, 2024, changes in its board of directors and executive compensation. Specifically, the company elected a new director, Ms. Pamela A. Pure, and approved a new employment agreement for its Chief Medical Officer, Dr. David M. Schreiner, effective October 1, 2024, which includes a base salary of $500,000 and potential bonuses.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and leadership stability.
Key Numbers
- 2024-09-27 — Report Date (Date of the earliest event reported in the 8-K filing.)
- $500,000 — CMO Base Salary (Annual base salary for Dr. David M. Schreiner under his new employment agreement.)
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- Pamela A. Pure (person) — Newly elected director
- David M. Schreiner (person) — Chief Medical Officer
- $500,000 (dollar_amount) — Dr. Schreiner's base salary
FAQ
Who is the newly elected director at Teladoc Health?
Ms. Pamela A. Pure was elected as a new director.
What is the effective date of Dr. David M. Schreiner's new employment agreement?
The new employment agreement for Dr. David M. Schreiner is effective October 1, 2024.
What is the base salary for Teladoc Health's Chief Medical Officer?
Dr. David M. Schreiner's base salary is $500,000 per year.
What is the primary purpose of this 8-K filing?
The filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
In which state is Teladoc Health, Inc. incorporated?
Teladoc Health, Inc. is incorporated in Delaware.
From the Filing
0001477449-24-000216.txt : 20241001 0001477449-24-000216.hdr.sgml : 20241001 20241001160506 ACCESSION NUMBER: 0001477449-24-000216 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240927 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20241001 DATE AS OF CHANGE: 20241001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241343225 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240927.htm 8-K tdoc-20240927 FALSE 0001477449 0001477449 2024-09-27 2024-09-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 27, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification Number) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act. Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure. Mr. Waters' resignation is effective on the close of business on December 31, 2024 (the “Separation Date”). The Company thanks Mr. Waters for his service. In connection with Mr. Waters's resignation, the Co